CSIRO signs global licensing agreement for Reversible Addition-Fragmentation chain Transfer technology

NewsGuard 100/100 Score

CSIRO has signed a global licensing agreement for its patented RAFT technology. Reversible Addition-Fragmentation chain Transfer (or RAFT) technology is an elegant and powerful polymerisation process that has given rise to a new branch of polymer chemistry.

RAFT enables the development of very complex molecules that can be used for a wide range of products. The technology is already generating major improvements in the areas of coatings and paints, electroactive materials, fuel additives, biomaterials, polymer synthesis, personal care, drug delivery agents and car components.

About 3200 papers have been published on RAFT developments, coupled with over 200 patents granted to research and commercial institutions globally.

Monomer Polymer, a US company which specialises in manufacturing specialty monomers and sophisticated polymers has agreed to market the technology worldwide. Monomer-Polymer and Dajac Labs CEO Stephen Bell said having access to RAFT technology will allow the company to "undertake controlled radical polymerizations and consequently, create additional success and opportunity in material development".

Additionally, Monomer-Polymer said that the licensing agreement would enable the company to strengthen their position as a key player in the synthesis, development and scale-up of specialty monomers and resulting polymer systems. A unique aspect of Monomer-Polymer's chemistries is the internal expertise with organosilanes which should open up unique uses of RAFT to create polymers with organosilicon functionalities in the architecture.

"This new technology is creating global impact and has been licensed by a wide range of Australian and multinational companies," CSIRO's Business Development Manager for RAFT Kate Dawson said.

Source: CSIRO Australia

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates